Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

High-Content Protein Expression Profiling in Tumor Biopsies to Guide Precision Oncology Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

High-Content Protein Expression Profiling in Tumor Biopsies to Guide Precision Oncology Therapies

High-Content Protein Expression Profiling for Precision Oncology

CELL & GENE | RNA | BIOLOGICS

Quantifying Proteomic Complexity to Guide Therapeutic Strategy.

    What platforms do you use for multiplex protein expression analysis in FFPE tissue?

    A: We deploy a range of validated platforms including multiplex immunofluorescence (mIF) and imaging mass cytometry (IMC). For deep proteomic quantification, we utilize proprietary liquid chromatography-mass spectrometry (LC-MS) workflows tailored for complex tissue matrices.

    How do you ensure quantitative accuracy for low-abundance or post-translationally modified proteins?

    A: Our GxP-compliant bioanalytical methods rely on stable isotope-labeled internal standards and multi-point calibration curves. We develop custom assays to target specific protein isoforms and post-translational modifications, ensuring high specificity and sensitivity.

    Can your assays differentiate between an exogenous therapeutic protein and its endogenous counterpart?

    A: Yes. We develop highly specific assays, often at the peptide level for mass spectrometry, that target unique sequences or tags on the therapeutic protein. This strategy, validated in our work with gene therapies, allows for precise quantification of the delivered biologic without interference from endogenous proteins.

    What are the sample requirements and turnaround times for a multi-analyte tumor biopsy profile?

    A: Sample requirements vary by platform, but a single FFPE slide or a small core needle biopsy is often sufficient. Timelines for analysis and custom assay development are established on a project-specific basis to align with your program goals.

We provide quantitative, multiplexed protein expression data from tumor biopsies to de-risk clinical development and inform patient stratification strategies. By moving beyond qualitative assessments, our high-content profiling services deliver the precise bioanalytical data required to understand mechanism of action, confirm target engagement, and identify predictive biomarkers for advanced oncology therapeutics.

Defining Pharmacodynamic Response in the Tumor Microenvironment

Evaluating the pharmacodynamic effect of a novel oncology agent requires a precise understanding of its impact on the tumor microenvironment (TME). Traditional single-analyte histology methods provide limited, often qualitative, data that fails to capture the complex interplay between tumor cells, immune infiltrates, and the surrounding stroma. This data gap can obscure true target engagement and lead to ambiguous decision-making during preclinical and early clinical phases.

Our approach utilizes high-content imaging and mass spectrometry to simultaneously quantify dozens of protein biomarkers from a single tissue section. This spatially resolved, quantitative data provides a comprehensive profile of cellular composition, signaling pathway activation, and the functional state of the TME. These analyses are conducted within our >100,000 sq ft GxP-compliant facility, ensuring data integrity for regulatory submissions.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Precision Assays for Complex Biologics

The challenge of protein quantification is amplified with biologic therapies, where an exogenous protein must be measured against a background of endogenous counterparts. As demonstrated in gene therapy applications, developing species-specific mass spectrometry methods is a robust strategy for quantifying therapeutic protein expression with high fidelity (PMID: 37891254). This principle is directly applicable to oncology, enabling accurate measurement of therapeutic antibodies, cell therapy-derived proteins, or other biologics within the tumor.

This level of bioanalytical rigor supports an accelerated development path. Our programs are designed to deliver an IND-ready data package within an 18-24 month timeline. While the Franklin Biolabs brand was established in 2024, our scientific leadership team’s methods have contributed to a 100% IND success rate for sponsor programs since 2019. Transforming complex proteomic data into clear, actionable insights is a core component of this success, accelerating clinical validation for our sponsors.

Comparative Methodologies for Protein Expression Analysis

Parameter Traditional Histology (IHC) High-Content Profiling (mIF / LC-MS)
Plex Level Single-plex or low-plex (2-4 analytes) High-plex (5-40+ analytes)
Data Output Qualitative or semi-quantitative (H-score) Fully quantitative (intensity, counts, concentration)
Spatial Context Preserved for single analyte Preserved (mIF) or homogenized (LC-MS)
Application Routine confirmation of target presence Deep TME characterization, PD monitoring, biomarker ID

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities